<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: further described herein", fill: "#696969"},
{source: "1: further described herein", target: "1: uncertainties", fill: "#696969"},
{source: "1: uncertainties", target: "1: following specific risks", fill: "#696969"},
{source: "1: following specific risks", target: "1: highly concentrated", fill: "#696969"},
{source: "1: highly concentrated", target: "1: two largest collaborators", fill: "#696969"},
{source: "1: further described herein", target: "2: fulltime employee funding from", fill: "#ffef00"},
{source: "2: fulltime employee funding from", target: "2: ScheringPlough ", fill: "#ffef00"},
{source: "2: ScheringPlough ", target: "2: termination", fill: "#ffef00"},
{source: "2: termination", target: "2: collaboration with", fill: "#ffef00"},
{source: "2: collaboration with", target: "2: currently conducted financial", fill: "#ffef00"},
{source: "2: currently conducted financial", target: "2: operations", fill: "#ffef00"},
{source: "2: operations", target: "2: relationships", fill: "#ffef00"},
{source: "2: fulltime employee funding from", target: "3: December ", fill: "#ff4500"},
{source: "3: December ", target: "3: earned approximately", fill: "#ff4500"},
{source: "3: earned approximately", target: "3: revenue under", fill: "#ff4500"},
{source: "3: revenue under", target: "3: collaboration agreements with two collaborators", fill: "#ff4500"},
{source: "3: December ", target: "15: December ", fill: "#03a"},
{source: "15: December ", target: "15: milestones", fill: "#03a"},
{source: "15: milestones", target: "15: success fees under", fill: "#03a"},
{source: "15: success fees under", target: "15: research collaboration agreements with", fill: "#03a"},
{source: "15: research collaboration agreements with", target: "15: second largest", fill: "#03a"},
{source: "15: second largest", target: "15: collaborator", fill: "#03a"},
{source: "15: December ", target: "24: consume available capital resources", fill: "#30ba8f"},
{source: "24: consume available capital resources", target: "25: ScheringPlough ", fill: "#ffa700"},
{source: "25: ScheringPlough ", target: "25: collaborations", fill: "#ffa700"},
{source: "25: collaborations", target: "25: existing collaborative relationships particularly", fill: "#ffa700"},
{source: "25: existing collaborative relationships particularly", target: "25: relationships", fill: "#ffa700"},
{source: "25: relationships", target: "25: connection with", fill: "#ffa700"},
{source: "25: connection with", target: "25: drug discovery", fill: "#ffa700"},
{source: "25: drug discovery", target: "25: development", fill: "#ffa700"},
{source: "25: development", target: "25: activities", fill: "#ffa700"},
{source: "25: activities", target: "25: acquisitions", fill: "#ffa700"},
{source: "25: acquisitions", target: "25: businesses", fill: "#ffa700"},
{source: "25: businesses", target: "25: candidates", fill: "#ffa700"},
{source: "25: candidates", target: "25: technologies", fill: "#ffa700"},
{source: "25: technologies", target: "25: comply with certain covenants", fill: "#ffa700"},
{source: "25: comply with certain covenants", target: "25: obligations", fill: "#ffa700"},
{source: "25: obligations", target: "25: transaction", fill: "#ffa700"},
{source: "25: transaction", target: "25: additional capital equipment", fill: "#ffa700"},
{source: "25: additional capital equipment", target: "25: competing technological", fill: "#ffa700"},
{source: "25: competing technological", target: "25: market developments", fill: "#ffa700"},
{source: "25: market developments", target: "25: filing prosecuting defending", fill: "#ffa700"},
{source: "25: filing prosecuting defending", target: "25: enforcing patent", fill: "#ffa700"},
{source: "25: enforcing patent", target: "25: intellectual property rights", fill: "#ffa700"},
{source: "25: intellectual property rights", target: "25: litigation", fill: "#ffa700"},
{source: "25: ScheringPlough ", target: "39: Currently ", fill: "#c72c48"},
{source: "39: Currently ", target: "39: collaborators", fill: "#c72c48"},
{source: "39: collaborators", target: "39: three programs comprised", fill: "#c72c48"},
{source: "39: three programs comprised", target: "39: four compounds into clinical trials", fill: "#c72c48"},
{source: "39: Currently ", target: "START_HERE", fill: "#c72c48"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bleiburg_repatriations">Bleiburg repatriations</a></td>
      <td>In May 1945, after the end of World War II in Europe, during which Yugoslavia had been occupied by the Axis powers, tens of thousands of soldiers and civilians associated with the Axis powers fled Yugoslavia to Austria as the Soviet Union (Red Army) and Yugoslav Partisans took control. When they reached Allied-occupied Austria, the British refused to accept their surrender and directed them to the Partisans instead despite knowing that they would be killed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots. Italy still prohibits offensive strikes, and reserves the right to veto U.S. missions.2 JanuaryIndian aerial surveillance detected gunmen entering an Indian Air Force base at Pathankot, and their security forces exchange fire with them in a housing area.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_7">December 7</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_software">Collaborative software</a></td>
      <td>Collaborative software or groupware is application software designed to help people working on a common task to attain their goals. One of the earliest definitions of groupware is "intentional group processes plus software to support them".As regards available interaction, collaborative software may be divided into: real-time collaborative editing platforms that allow multiple users to engage in live, simultaneous and reversible editing of a single file (usually a document),  and version control (also known as revision control and source control) platforms, which allow separate users to make parallel edits to a file, while preserving every saved edit by every user as multiple files (that are variants of the original file).Collaborative software is a broad concept that overlaps considerably with computer-supported cooperative work (CSCW).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_writing">Collaborative writing</a></td>
      <td>Collaborative writing, or collabwriting is a method of group work that takes place in the workplace and in the classroom. Researchers expand the idea of collaborative writing beyond groups working together to complete a writing task.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborators_(Battlestar_Galactica)">Collaborators (Battlestar Galactica)</a></td>
      <td>"Collaborators"  is the fifth episode of the third season from the science fiction television series Battlestar Galactica.\nThis is the first episode of season 3 to include a survivor count, at 41,435, down considerably from the 49,550 shown in "Lay Down Your Burdens" (Part 2).</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PHARMACOPEIA DRUG DISCOVERY INC      ITEM 1A        RISK FACTORS       As <font color="blue">further described herein</font>, our performance and financial results are     subject  to risks and <font color="blue">uncertainties</font> including, but not limited to, the     <font color="blue">following specific risks</font>:       RISKS RELATED TO OUR BUSINESS AND INDUSTRY       Our revenue is <font color="blue">highly concentrated</font> in our <font color="blue">two largest <font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>The     planned cessation of full-time employee <font color="blue">funding from</font> Schering-Plough or the     <font color="blue">termination</font> of our <font color="blue"><font color="blue">collaboration</font> with</font> NV Organon would have a material     adverse effect on our business as it is <font color="blue">currently conducted</font>, financial     condition and results of <font color="blue">operations</font> if we are unable to replace the funding     from these <font color="blue"><font color="blue">relationship</font>s</font></td>
    </tr>
    <tr>
      <td>During the year ended year ended <font color="blue">December </font>31, 2005, we <font color="blue">earned <font color="blue">approximately</font></font>     dlra16dtta4 million, or <font color="blue">approximately</font> 80prca of our revenue, under our research     <font color="blue"><font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font> with two <font color="blue">collaborator</font>s</font>, Schering-Plough and NV     Organon</td>
    </tr>
    <tr>
      <td>During the year ended <font color="blue">December </font>31, 2005, we <font color="blue">earned <font color="blue">approximately</font></font>     dlra9dtta9 million, or 48prca of our revenue, of which dlra8dtta9 million was full-time     employee (FTE) funding and dlra1dtta0 million was milestone payments, under our     research  <font color="blue">collaboration</font>  <font color="blue"><font color="blue">agreement</font>s</font>  with  Schering-Plough, one of our     longest-standing <font color="blue"><font color="blue">collaborative</font> partners</font></td>
    </tr>
    <tr>
      <td>Our longstanding research <font color="blue">collaboration</font>s with Schering-Plough will reach     maturity in August 2006</td>
    </tr>
    <tr>
      <td>Currently, we are planning for full-time employee     (FTE) <font color="blue">funding from</font> the Schering-Plough <font color="blue">collaboration</font>s ceasing at that time</td>
    </tr>
    <tr>
      <td>The planned cessation of FTE <font color="blue">funding will</font> have <font color="blue">no <font color="blue">impact on</font></font> other areas of     the <font color="blue">collaboration</font>s, including the ongoing Phase I <font color="blue">clinical trial</font> in an     <font color="blue">inflammatory indication</font> and <font color="blue">multiple preclinical programs</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will continue</font>     to be entitled to payments resulting from the <font color="blue">successful <font color="blue">achievement</font> by</font>     Schering-Plough, if any, of preclinical and <font color="blue">clinical <font color="blue">milestones</font> as well as</font>     <font color="blue"><font color="blue"><font color="blue">royalty payments</font> from</font> sales</font>, if any, of products resulting <font color="blue">from compounds</font>     already  delivered  by  us  and  <font color="blue">accepted by</font> Schering-Plough under the     <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently discussing potential <font color="blue">partnerships</font> with</font>     <font color="blue">multiple companies</font> to establish broad, multi-year alliances that, <font color="blue">consistent</font>     with our business strategy, have the potential to <font color="blue">provide us with</font> a larger     share  of  product ownership than previous <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>There is no     assurance that we will be successful in <font color="blue">establishing such alliances</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Failure  </font>   </font>to replace the <font color="blue">revenue from</font> the Schering-Plough <font color="blue">collaboration</font>s would have a     material adverse effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Revenue <font color="blue">recognition</font> of     <font color="blue">funding from</font> any <font color="blue">new alliances may</font> be different from revenue <font color="blue">recognition</font> of     <font color="blue">funding from</font> the Schering-Plough <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>Failure to replace the     funding  from the Schering-Plough <font color="blue">collaboration</font>s would have a material     adverse  effect  on  our business as it is <font color="blue">currently conducted</font> and our     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available, we may be required     to curtail <font color="blue">operations</font> <font color="blue"><font color="blue">significant</font>ly</font> or to obtain <font color="blue">funds by <font color="blue">entering into</font></font>     <font color="blue"><font color="blue">arrangement</font>s with <font color="blue"><font color="blue">collaborative</font> partners</font></font> or others that may require us to     <font color="blue">relinquish rights</font> to certain of our <font color="blue">technologies</font>, products or potential     markets that we would not <font color="blue">otherwise relinquish</font></td>
    </tr>
    <tr>
      <td>During  the year ended <font color="blue">December </font>31, 2005, we <font color="blue">earned <font color="blue">approximately</font></font> dlra6dtta5     million, or 32prca of our revenue, of which dlra4dtta0 million was FTE funding and     dlra2dtta5 million was <font color="blue">milestones</font> and success fees, under       18     ______________________________________________________________________       our research <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font> with NV Organon, our <font color="blue">second largest</font>     <font color="blue">collaborator</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">principal <font color="blue">agreement</font> with</font> Organon, <font color="blue">entered into</font> in <font color="blue"><font color="blue">February </font>    </font>2002, has a stated <font color="blue">research term</font> of <font color="blue">five years</font></td>
    </tr>
    <tr>
      <td>Failure to replace the     <font color="blue">funding from</font> <font color="blue">the Organon </font><font color="blue">collaboration</font>s would have a material adverse effect     on our business as it is <font color="blue">currently conducted</font> and our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">adequate funds</font> are not available, we may be required to curtail <font color="blue">operations</font>     <font color="blue"><font color="blue">significant</font>ly</font>  or  to  obtain <font color="blue">funds by <font color="blue">entering into</font></font> <font color="blue">arrangement</font>s with     <font color="blue"><font color="blue">collaborative</font> partners</font> or others that may require us to <font color="blue">relinquish rights</font> to     certain of our <font color="blue">technologies</font>, products or <font color="blue">potential markets</font> that we would not     <font color="blue">otherwise relinquish</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">consume cash</font> more <font color="blue">quickly than</font> expected, we may be unable to raise     <font color="blue"><font color="blue">additional</font> capital</font> and we may be forced to curtail <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>On July 28, 2005, we <font color="blue">entered into</font> purchase <font color="blue"><font color="blue">agreement</font>s</font> to sell an aggregate     2cmam470cmam000  shares  of  newly  issued  common  stock  (the “Shares”) to     <font color="blue">institutional</font>  investors  at  a price of dlra3dtta43 per share (the “Private     Placement”)</td>
    </tr>
    <tr>
      <td>On August 1, 2005, we sold the Shares and realized gross     proceeds  of <font color="blue">approximately</font> dlra8dtta5 million from <font color="blue">the Private Placement</font></td>
    </tr>
    <tr>
      <td>We     received  net  proceeds of <font color="blue">approximately</font> dlra7dtta7 million from the Private     Placement after <font color="blue">deducting fees payable</font> to the <font color="blue">placement agent</font> and other     <font color="blue"><font color="blue">transaction</font> expenses</font></td>
    </tr>
    <tr>
      <td>We anticipate that our <font color="blue">capital resources</font>, including our existing cash, cash     <font color="blue">equivalents</font>  and  marketable  securities  as  of  <font color="blue">December </font>31, 2005 of     <font color="blue">approximately</font> dlra30dtta4 million, will be adequate to fund our <font color="blue">operations</font> at     their current levels at least through 2006</td>
    </tr>
    <tr>
      <td>However, changes may occur that     would cause us to consume available <font color="blue">capital resources</font> before that time</td>
    </tr>
    <tr>
      <td>Examples of relevant potential changes in our <font color="blue">capital resources</font> include:       ·        the  planned  cessation  of  FTE <font color="blue">funding from</font> Schering-Plough     <font color="blue">collaboration</font>s in August 2006;       ·       changes in other existing <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font>, <font color="blue">particularly</font>     with Organon, including the funding we receive in <font color="blue"><font color="blue">connection</font> with</font> those     <font color="blue"><font color="blue">relationship</font>s</font>;       ·        the  costs associated with our <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font>     <font color="blue">activities</font>;       ·        <font color="blue"><font color="blue">acquisition</font>s</font>  of  other  <font color="blue">businesses</font>,  product  <font color="blue">candidates</font>  or     <font color="blue">technologies</font>;       ·       penalties we may be required to pay the purchasers in the Private     Placement  if we fail to <font color="blue">comply with certain covenants</font> and <font color="blue">obligations</font>     related to that <font color="blue">transaction</font>;       ·       the purchase of <font color="blue"><font color="blue">additional</font> capital</font> equipment;       ·       <font color="blue">competing <font color="blue">technological</font></font> and market <font color="blue">development</font>s;       ·       the cost of filing, prosecuting, defending and <font color="blue">enforcing patent</font>     claims and other <font color="blue"><font color="blue">intellectual</font> property rights</font>, and the outcome of related     <font color="blue">litigation</font>; and       ·       the progress of our milestone and royalty producing <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We intend to raise <font color="blue"><font color="blue">additional</font> capital</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">capital could</font> be <font color="blue">raised through</font>     public or <font color="blue">private financings involving debt</font> or common or other classes of     our equity</td>
    </tr>
    <tr>
      <td>Any issuance of <font color="blue"><font color="blue">equity securities</font> would dilute</font> our current     <font color="blue">stockholders</font>’ percentage ownership of us</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, there     were <font color="blue">stock options outstanding</font> to purchase <font color="blue">approximately</font> 4cmam280cmam000 shares of     our <font color="blue">common stock</font> and <font color="blue">approximately</font> 10cmam000 shares of <font color="blue">unvested restricted</font>     <font color="blue">stock issued under</font> our <font color="blue">various equity compensation</font> plans</td>
    </tr>
    <tr>
      <td>These equity     <font color="blue">instruments</font>  represent  <font color="blue">approximately</font> 29prca of our <font color="blue">shares outstanding at</font>     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">significant</font> dilution represented by</font> our outstanding     equity  <font color="blue">compensation awards may</font> make it more <font color="blue">difficult</font> for us to raise     <font color="blue"><font color="blue">additional</font> capital</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">capital may</font> not be <font color="blue">available on</font> favorable     terms, or at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available, we may be required to     curtail  <font color="blue">operations</font>  <font color="blue"><font color="blue">significant</font>ly</font> or to obtain <font color="blue">funds by <font color="blue">entering into</font></font>     <font color="blue"><font color="blue">arrangement</font>s with <font color="blue"><font color="blue">collaborative</font> partners</font></font> or others that may require us to     <font color="blue">relinquish rights</font> to certain of our <font color="blue">technologies</font>, products or potential     markets that we would not <font color="blue">otherwise relinquish</font></td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       The <font color="blue">development</font> of our internal and <font color="blue"><font color="blue">collaborative</font> products</font> is at an early     stage and is uncertain</td>
    </tr>
    <tr>
      <td>Drug <font color="blue">development</font> is a <font color="blue">highly uncertain process</font></td>
    </tr>
    <tr>
      <td>Our approach and <font color="blue">technology</font>     may never result in a <font color="blue">commercial drug</font></td>
    </tr>
    <tr>
      <td>None of our programs has resulted in     products that have received <font color="blue">regulatory</font> approval for commercial sale</td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, none of our <font color="blue">internal programs</font> had <font color="blue">advanced into clinical</font>     trials (ie, human testing)</td>
    </tr>
    <tr>
      <td><font color="blue">Currently </font>our <font color="blue">collaborator</font>s have advanced     three programs (comprised of four compounds) into <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>All of     our therapeutic <font color="blue">candidates</font>, including these clinical <font color="blue">candidates</font>, face the     substantial risks of failure inherent in the drug <font color="blue">development</font> process</td>
    </tr>
    <tr>
      <td>Any     potential <font color="blue">pharmaceutical</font> product emanating from one of our internal or     <font color="blue">collaborative</font>  programs  <font color="blue">must satisfy rigorous standards</font> of safety and     efficacy before the <font color="blue"><font color="blue">United States</font> </font>Food and Drug Administration (FDA) and     foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> will approve them for commercial use</td>
    </tr>
    <tr>
      <td>To     satisfy  these standards, <font color="blue">significant</font> <font color="blue">additional</font> research, preclinical     studies (ie, animal testing) and <font color="blue">clinical trial</font>s will be required</td>
    </tr>
    <tr>
      <td>Our internal and <font color="blue">collaborative</font> programs are in <font color="blue"><font color="blue">early stage</font>s relative</font> to     <font color="blue">generating</font> a <font color="blue">commercial product</font></td>
    </tr>
    <tr>
      <td>Therefore, we and our <font color="blue">collaborator</font>s must     engage in <font color="blue">significant</font>, time-consuming and <font color="blue">costly research</font> and <font color="blue">development</font>     <font color="blue">efforts followed by</font> our and our <font color="blue">collaborator</font>s’ <font color="blue">application</font>s for and receipt     of, <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>Consequently, we do not expect <font color="blue">compounds from</font>     these <font color="blue">development</font> <font color="blue">activities</font> to result in <font color="blue">commercially available products</font>     for many years, if at all</td>
    </tr>
    <tr>
      <td>Our business is <font color="blue">highly dependent upon</font> the extent to which the <font color="blue">pharmaceutical</font>     and bio<font color="blue">technology</font> <font color="blue">industries</font> <font color="blue">collaborate with</font> <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font>     companies for one or more aspects of their <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font>     process</td>
    </tr>
    <tr>
      <td>Our  revenue  depends  to  a  large <font color="blue">extent on research</font> and <font color="blue">development</font>     <font color="blue">expenditures</font>  by  the <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">capabilities</font> include aspects of the <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font> process     that <font color="blue">pharmaceutical</font> companies have <font color="blue">traditionally</font> performed <font color="blue">internally</font></td>
    </tr>
    <tr>
      <td>Although there is a history among <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies     of <font color="blue">outsourcing <font color="blue">drug research</font></font> and <font color="blue">development</font> functions, this <font color="blue">practice may</font>     not continue</td>
    </tr>
    <tr>
      <td>The <font color="blue">willingness</font> of these companies to expand or continue <font color="blue">collaboration</font>s to     enhance  their research and <font color="blue">development</font> <font color="blue">activities</font> is <font color="blue"><font color="blue">based on</font> certain</font>     factors that are beyond our control</td>
    </tr>
    <tr>
      <td>While we are unaware of a specific     reason that any of the <font color="blue"><font color="blue">following factors</font> will</font> have a material <font color="blue">impact on</font> the     <font color="blue">willingness</font> of current or potential <font color="blue">collaborator</font>s to expand or continue     <font color="blue">collaboration</font>s, examples of <font color="blue">relevant factors</font> include <font color="blue">collaborator</font>s’ changing     spending  priorities  among  <font color="blue">various types</font> of research <font color="blue">activities</font>, the     <font color="blue">increased presence</font> of <font color="blue">offshore companies</font> that <font color="blue">conduct research</font> and have     lower  FTE costs than ours, their ability to hire and retain qualified     <font color="blue">scientists</font>,  their approach regarding <font color="blue">expenditures</font> during recessionary     periods and their policies regarding the balance of research <font color="blue">expenditures</font>     versus  cost  <font color="blue">containment</font></td>
    </tr>
    <tr>
      <td>Also,  general  economic  downturns in our     <font color="blue">collaborator</font>s’ <font color="blue">industries</font>, adverse changes in the <font color="blue">regulatory</font> environment,     the <font color="blue">adverse impact</font> of product <font color="blue">litigation</font> on our <font color="blue">collaborator</font>s’ <font color="blue">businesses</font> or     any decrease in our research and <font color="blue">development</font> <font color="blue">expenditures</font> could harm our     <font color="blue">operations</font>, as could increased <font color="blue">popularity</font> of <font color="blue">management</font> theories, which     counsel  <font color="blue">against outsourcing</font> of critical business functions</td>
    </tr>
    <tr>
      <td><font color="blue">Continued     </font><font color="blue">consolidation</font> in the <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> <font color="blue">industries</font> may further     decrease the number of potential <font color="blue">collaborator</font>s for us</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">popularity</font> of scientific thinking that <font color="blue">disfavors elements</font> of our <font color="blue">technology</font>     platform, such as large diverse libraries, could negatively impact our     business</td>
    </tr>
    <tr>
      <td>Any decrease in <font color="blue">drug <font color="blue">discovery</font></font> spending by <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> companies could cause our revenue to decline</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">collaborate with</font> large <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     <font color="blue">companies will <font color="blue">depend on</font></font> many factors, including our ability to:       ·       discover and develop high-quality drug <font color="blue">candidates</font>;       ·       identify and utilize <font color="blue">scientists</font> and <font color="blue">technologies</font> that are of the     <font color="blue">highest caliber</font>; and       ·       achieve results in a timely fashion, with acceptable quality and at     an acceptable cost</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       The importance of these factors varies from <font color="blue">collaborator</font> to <font color="blue">collaborator</font>,     and we may be unable to meet any or all of them for some or all of our     <font color="blue">collaborator</font>s in the future</td>
    </tr>
    <tr>
      <td>If our <font color="blue">collaborator</font>s are not able to <font color="blue">successfully</font> develop our existing     clinical <font color="blue">candidates</font>, our business will be harmed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborator</font>s, Bristol-Myers Squibb Company, Daiichi Pharmaceutical Co</td>
    </tr>
    <tr>
      <td>and Schering-Plough Corporation, currently are performing <font color="blue">clinical trial</font>s of     prospective <font color="blue">pharmaceutical</font> products containing our <font color="blue"><font color="blue">proprietary</font> compounds</font></td>
    </tr>
    <tr>
      <td>In     each case, the <font color="blue">collaborator</font> is responsible for the <font color="blue">development</font> of these     <font color="blue">potential products</font>, the level of <font color="blue">resources devoted</font> to such <font color="blue">development</font> and     the <font color="blue">decision as</font> to when, or whether, such <font color="blue">development</font> should cease</td>
    </tr>
    <tr>
      <td>Numerous <font color="blue"><font color="blue">additional</font> studies</font> are <font color="blue">necessary</font> to support the further <font color="blue">development</font>     of these product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Results <font color="blue">from pre<font color="blue">clinical studies</font> conducted</font> to     date on these product <font color="blue">candidates</font> are not <font color="blue">necessarily indicative</font> of the     results that may be obtained in <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>Clinical results could     cause our <font color="blue">collaborator</font>s to <font color="blue">discontinue</font> or limit <font color="blue">development</font> of these product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>For example, in November 2005, Schering-Plough <font color="blue">informed us</font> that     it <font color="blue">discontinue</font>d the Phase I <font color="blue">clinical trial</font>s it commenced in <font color="blue">December </font>2003     for the <font color="blue">clinical compound targeting</font> a respiratory indication, which was     developed <font color="blue">from leads from</font> our <font color="blue"><font color="blue">collaboration</font> with</font> Schering-Plough</td>
    </tr>
    <tr>
      <td>There can     be no assurance that Bristol-Myers Squibb, Daiichi or Schering-Plough will     continue to develop the <font color="blue">current clinical programs</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">collaborator</font>s may pursue alternative <font color="blue">technologies</font> or drug     <font color="blue">candidates</font>,  <font color="blue">either on</font> their own or in <font color="blue"><font color="blue">collaboration</font> with</font> others, that     <font color="blue">compete with</font> the clinical <font color="blue">candidates</font> on which they <font color="blue">collaborate with</font> us</td>
    </tr>
    <tr>
      <td>If     our <font color="blue">collaborator</font>s do not continue their <font color="blue">development</font> efforts or if such     efforts do not result in positive clinical results, we will not receive     <font color="blue">additional</font>  milestone and <font color="blue"><font color="blue">royalty payments</font> from</font> those efforts, and our     business will be harmed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">stock price may</font> be volatile, and your <font color="blue">investment</font> in our <font color="blue">stock could</font>     decline in value</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our <font color="blue">common stock</font> has been <font color="blue">highly volatile</font> and may     continue  to  be  <font color="blue">highly volatile</font> in the future</td>
    </tr>
    <tr>
      <td>During the year ended     <font color="blue">December </font>31, 2005 the closing price was dlra3dtta06 per share at its low point in     November 2005 and dlra5dtta81 per share at its high point in January 2005</td>
    </tr>
    <tr>
      <td>Our     quarterly operating results, changes in <font color="blue">general conditions</font> in the economy or     the <font color="blue">financial markets</font>, and other <font color="blue">development</font>s affecting our <font color="blue">competitors</font> or     us  could  cause  the  market  price  of our <font color="blue">common stock</font> to fluctuate     <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, the <font color="blue">stock market</font> has experienced <font color="blue">significant</font>     price and <font color="blue">volume fluctuations</font></td>
    </tr>
    <tr>
      <td>While we are unaware of a <font color="blue">specific reason</font> that any of the <font color="blue">following factors</font>     will have a material <font color="blue">impact on</font> our stock price, the <font color="blue">following factors</font>, in     addition to the <font color="blue">factors described</font> in the other <font color="blue">risk factors contained</font> in     this report, may have a <font color="blue">significant</font> <font color="blue">impact on</font> the <font color="blue">market price</font> of our common     stock:       ·       <font color="blue">publicity concerning</font> the status of <font color="blue"><font color="blue">potential drug</font> products under</font>     <font color="blue">development</font>  by  us  or our <font color="blue">collaborator</font>s or our <font color="blue">competitors</font> and their     partners;       ·       reduction, <font color="blue">termination</font> or expiration of our <font color="blue">collaboration</font>s;       ·       <font color="blue"><font color="blue">announcement</font>s</font> by us or our <font color="blue">competitors</font> of <font color="blue">significant</font> <font color="blue"><font color="blue">acquisition</font>s</font>,     <font color="blue">strategic <font color="blue">partnerships</font></font> or <font color="blue">joint ventures</font>;       ·        <font color="blue"><font color="blue">announcement</font>s</font>  of <font color="blue"><font color="blue">technological</font> innovations</font> or <font color="blue">new commercial</font>     <font color="blue">products by</font> our <font color="blue">competitors</font> or us;       ·       <font color="blue">development</font>s concerning <font color="blue">proprietary</font> rights, including patents;       ·       <font color="blue">litigation</font>;       ·       economic and other <font color="blue">external factors</font> or other <font color="blue">disasters</font> or crises;       21     ______________________________________________________________________       ·       actual or anticipated period-to-period fluctuations in our financial     results;       ·       changes in financial estimates prepared <font color="blue">by securities analysts</font>;       ·       <font color="blue">differences</font> in the <font color="blue">valuations assigned by</font> the <font color="blue">equity markets</font> and, in     particular,  the  bio<font color="blue">pharmaceutical</font>  sector  of the <font color="blue">equity markets</font>, to     bio<font color="blue">pharmaceutical</font> companies like us that have more <font color="blue">drug <font color="blue">discovery</font></font> than drug     <font color="blue">development</font> <font color="blue">capabilities</font>; and       ·       the <font color="blue">general performance</font> of the <font color="blue">equity markets</font> and, in particular,     the bio<font color="blue">pharmaceutical</font> sector of the <font color="blue">equity markets</font></td>
    </tr>
    <tr>
      <td>We  had  net  losses  in <font color="blue">recent years</font>, and our <font color="blue">future <font color="blue">profitability</font></font> is     uncertain</td>
    </tr>
    <tr>
      <td>For the <font color="blue">fiscal year</font>s ended <font color="blue">December </font>31, 2005, 2004 and 2003, we had net     losses of <font color="blue">approximately</font> dlra17dtta1 million, dlra17dtta4 million and dlra2dtta8 million,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>The net loss for the year ended <font color="blue">December </font>31, 2005 was due to increased     corporate  overhead  costs, severance costs and our <font color="blue">increased focus on</font>     <font color="blue">internal research</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The net loss for the <font color="blue">fiscal year</font> ended     <font color="blue">December </font>31, 2004 included <font color="blue">restructuring</font> and other charges of dlra5dtta9 million</td>
    </tr>
    <tr>
      <td>Our longstanding research <font color="blue"><font color="blue">collaboration</font> with</font> Schering-Plough will reach     maturity in August 2006</td>
    </tr>
    <tr>
      <td>In addition, under the <font color="blue">principal <font color="blue">agreement</font> with</font> Organon, the <font color="blue">research term</font>     expires  in  <font color="blue">February </font>2007</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  replace the <font color="blue">revenue from</font> our     <font color="blue">collaboration</font>s  with Schering-Plough and Organon would have a material     adverse effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The adoption of the Financial Accounting Standards Board Statement Nodtta 123R     “Share-Based Payment” will have a <font color="blue">significant</font> <font color="blue">impact on</font> our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>This statement is <font color="blue">effective</font> for the <font color="blue">first interim</font> reporting     period after <font color="blue">December </font>15, 2005</td>
    </tr>
    <tr>
      <td>On a quarterly basis, our future operating results are likely to be highly     volatile  depending  upon  our  receipt of milestone payments from our     <font color="blue">collaborator</font>s</td>
    </tr>
    <tr>
      <td>We may not receive <font color="blue">milestone payments on</font> a <font color="blue">regular basis</font> or     at all</td>
    </tr>
    <tr>
      <td>Our ability to achieve <font color="blue">profitability</font>, if ever, will be <font color="blue"><font color="blue">significant</font>ly</font>     <font color="blue">impacted by</font> the level of <font color="blue">investment</font> we determine to make in our internal     <font color="blue"><font color="blue">proprietary</font> programs</font> in the <font color="blue">future as well as</font> the results of those programs</td>
    </tr>
    <tr>
      <td><font color="blue">Continuing </font><font color="blue">net losses may limit</font> our ability to fund our <font color="blue">operations</font>, and we     may not generate income from <font color="blue">operations</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Disputes  </font>may  arise  between  our partners and us as to royalties and     <font color="blue">milestones</font> to which we believe we are entitled</td>
    </tr>
    <tr>
      <td>The <font color="blue">compound basis</font> for drugs developed by a <font color="blue">partner may</font> be a <font color="blue">derivative</font> or     <font color="blue">optimized version</font> of the <font color="blue">compound screened</font> or <font color="blue">optimized by us</font></td>
    </tr>
    <tr>
      <td>While our     existing <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font> provide that we will receive milestone     payments and <font color="blue">royalties with respect</font> to <font color="blue">certain products</font> developed from     certain <font color="blue">derivative</font> compounds, there can be no assurance that <font color="blue">disputes will</font>     not arise over the <font color="blue">application</font> of <font color="blue">payment provisions</font> to <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that current or <font color="blue">future partners will</font> not pursue     alternative <font color="blue">technologies</font>, or develop alternative products <font color="blue">either on</font> their     own or in <font color="blue"><font color="blue">collaboration</font> with</font> others, including our <font color="blue">competitors</font>, as a means     for developing <font color="blue">treatments <font color="blue">based on</font></font> the <font color="blue">targets which</font> are the subject of the     <font color="blue">collaborative</font> <font color="blue">arrangement</font>s with us</td>
    </tr>
    <tr>
      <td>In addition, many of our <font color="blue"><font color="blue">agreement</font>s</font> that     provide for <font color="blue">potential <font color="blue">royalty payments</font></font> to <font color="blue">us also contain provisions</font> that     reduce our expected royalty if a partner is also required to pay a royalty     on a product to a <font color="blue">third party</font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       We may not <font color="blue">successfully</font> <font color="blue">enter into</font> <font color="blue">additional</font> <font color="blue">collaboration</font>s that allow us     to <font color="blue">participate</font> in the future success of our product <font color="blue">candidates</font> through     milestone, royalty and/or <font color="blue">license payments</font>, and we may never receive any     milestone, royalty and/or <font color="blue">license payments</font> under our current or any future     <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>One of our business strategies is to expand our <font color="blue">proprietary</font> pipeline of drug     <font color="blue">candidates</font> and to then <font color="blue">enter into</font> <font color="blue">collaboration</font>s for the <font color="blue">development</font> of     these drug <font color="blue">candidates</font> that <font color="blue">will allow us</font> to earn milestone, royalty and/or     <font color="blue">license payments</font> or otherwise share in <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">proprietary</font>     <font color="blue">drug <font color="blue">discovery</font></font> program is in its <font color="blue">early stage</font> of <font color="blue">development</font> and is unproven</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  have expended, and continue to expend, time and money on     internal  research and <font color="blue">development</font> programs, we may be <font color="blue">unsuccessful</font> in     creating valuable <font color="blue">proprietary</font> drug <font color="blue">candidates</font> that <font color="blue">would enable us</font> to form     <font color="blue">additional</font> <font color="blue">collaboration</font>s and receive milestone, royalty and/or license     payments</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaboration</font>s and <font color="blue">internal programs</font> may not result in the <font color="blue">discovery</font> of     <font color="blue">potential drug</font> <font color="blue">candidates</font> that will be safe or <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Although we have     received  license and <font color="blue">milestone fees</font> to date, we may never receive any     <font color="blue">royalty payments</font>, or any <font color="blue">additional</font> license and <font color="blue">milestone fees</font>, under our     current or any future <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>Our receipt of any <font color="blue">future milestone</font>,     royalty or <font color="blue">license payments</font> depends on many factors, including whether our     <font color="blue">collaborator</font>s desire to or are able to continue to pursue a <font color="blue">potential drug</font>     candidate and the <font color="blue">ultimate commercial success</font> of the drug</td>
    </tr>
    <tr>
      <td><font color="blue">Development </font>and     <font color="blue">commercialization</font>  of <font color="blue">potential drug</font> <font color="blue">candidates</font> depend not only on the     <font color="blue">achievement</font> of research <font color="blue">objectives</font> by our <font color="blue">collaborator</font>s and us, but also on     each  <font color="blue">collaborator</font>’s  financial,  <font color="blue">competitive</font>, marketing and strategic     <font color="blue">considerations</font> and regulation <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and other countries</td>
    </tr>
    <tr>
      <td>If     <font color="blue">unforeseen complications</font> arise in the <font color="blue">development</font> or <font color="blue">commercialization</font> of     the <font color="blue">potential drug</font> <font color="blue">candidates</font> by our <font color="blue">collaborator</font>s, we may not realize     milestone, royalty or <font color="blue">license payments</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">drug research</font> and <font color="blue">development</font> industry is highly <font color="blue">competitive</font> and subject     to <font color="blue">technological</font> change, and we may not have the resources <font color="blue">necessary</font> to     compete <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Many  of  our <font color="blue">competitors</font> have access to greater financial, technical,     research, marketing, sales, <font color="blue">distribution</font>, service and other <font color="blue">resources than</font>     we  do</td>
    </tr>
    <tr>
      <td>Moreover, the <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> <font color="blue">industries</font> are     <font color="blue">characterized</font> by <font color="blue">continuous</font> <font color="blue">technological</font> innovation</td>
    </tr>
    <tr>
      <td>We anticipate that we     <font color="blue">will face increased <font color="blue">competition</font></font> in the <font color="blue">future as new companies enter</font> the     market  and  our  <font color="blue">competitors</font>  make  advanced  <font color="blue">technologies</font> available</td>
    </tr>
    <tr>
      <td><font color="blue">Technological </font>advances or <font color="blue">entirely different approaches</font> that we or one or     more  of our <font color="blue">competitors</font> develop may render our products, services and     <font color="blue">expertise obsolete</font> or uneconomical</td>
    </tr>
    <tr>
      <td>Additionally, the existing approaches of     our <font color="blue">competitors</font> or new approaches or <font color="blue">technologies</font> that our <font color="blue">competitors</font>     develop may be more <font color="blue">effective</font> than those we develop</td>
    </tr>
    <tr>
      <td>We may not be able to     compete <font color="blue">successfully</font> with existing or future <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot manage</font> the multiple <font color="blue"><font color="blue">relationship</font>s</font> and <font color="blue">interests involved</font> in our     <font color="blue">collaborative</font> <font color="blue">arrangement</font>s and <font color="blue">internal programs</font>, our business, financial     condition and results of <font color="blue">operations</font> may be <font color="blue"><font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></font></td>
    </tr>
    <tr>
      <td>We may need to <font color="blue">successfully</font> structure and manage multiple <font color="blue">internal programs</font>     and <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font>, including maintaining <font color="blue"><font color="blue">confidential</font>ity</font> of     the research being performed for multiple <font color="blue">collaborator</font>s</td>
    </tr>
    <tr>
      <td>We may be unable to     <font color="blue">successfully</font> manage conflicts between competing drug <font color="blue">development</font> programs of     <font color="blue">third parties</font> to which we <font color="blue">offer services</font></td>
    </tr>
    <tr>
      <td>From time to time, more than one     of our <font color="blue">collaborator</font>s may want to perform <font color="blue">research concerning</font> the same or     <font color="blue">molecularly</font> similar <font color="blue">disease targets</font></td>
    </tr>
    <tr>
      <td>Because of that, we may be required to     reconcile our <font color="blue"><font color="blue">relationship</font>s</font> with those <font color="blue">collaborator</font>s, <font color="blue">particularly</font> if both     want to establish exclusive <font color="blue"><font color="blue">relationship</font>s</font> with us with respect to that     target or if one <font color="blue">collaborator</font> has an existing <font color="blue">arrangement</font> with us and the     other would like us to perform services regarding a <font color="blue">target restricted by</font>     that <font color="blue">arrangement</font></td>
    </tr>
    <tr>
      <td>Further, if we are working with a <font color="blue">collaborator</font> regarding a     <font color="blue">particular target</font>, another of our <font color="blue">collaborator</font>s may be <font color="blue">researching</font> the same     target in one of its <font color="blue">internal programs</font> of which we have no knowledge</td>
    </tr>
    <tr>
      <td>As a     result, potential conflicts involving us may arise due to this <font color="blue">competition</font>     between <font color="blue">collaborator</font>s in a <font color="blue">particular disease field</font> of interest</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       <font color="blue">Conflicts </font>also may arise between our <font color="blue">collaborator</font>s as to <font color="blue">proprietary</font> rights     to <font color="blue">particular compounds</font> in our libraries or as to <font color="blue">proprietary</font> rights to     <font color="blue">biological targets such as receptors</font> or <font color="blue">enzymes against which</font> we screen     compounds in our libraries</td>
    </tr>
    <tr>
      <td>The occurrence of conflicts, or the <font color="blue">perception</font>     of  conflicts,  could  have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">use hazardous materials</font> in a manner that causes injury or violates     laws, we may be liable for damages</td>
    </tr>
    <tr>
      <td>Our <font color="blue">activities</font> involve the use of <font color="blue">potentially harmful hazardous materials</font>,     <font color="blue">chemicals</font> and <font color="blue">various radioactive compounds</font></td>
    </tr>
    <tr>
      <td>These materials are utilized in     the performance of our assay <font color="blue">development</font>, high-throughput screening and     <font color="blue">chemistry <font color="blue">optimization services</font></font>, and include common organic solvents, such     as acetone, hexane, methylene chloride, acetonitrile, and isopropyl and     methyl  alcohol,  as  well  as  <font color="blue">common acids</font> and bases</td>
    </tr>
    <tr>
      <td>The waste from     <font color="blue">utilization</font> of these solvents and other materials is disposed of through     licensed third-party contractors</td>
    </tr>
    <tr>
      <td>Further, we utilize an <font color="blue">extremely wide</font>     variety of <font color="blue">chemicals</font> in the performance of our assay <font color="blue">development</font>, screening     and <font color="blue">optimization services</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">chemicals</font>, such as reagents, buffers and     inorganic  salts, typically are employed in extremely small amounts in     <font color="blue"><font color="blue">connection</font> with</font> the work performed in our <font color="blue">laboratories</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot completely</font>     eliminate the risk of <font color="blue">accidental <font color="blue">contamination</font></font> or <font color="blue">injury from</font> the use,     storage,  handling  or  disposal  of  these materials</td>
    </tr>
    <tr>
      <td>In the event of     <font color="blue">contamination</font> or injury, we could be held liable for damages that result</td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">insurance coverage against environmental hazards</font> arising from     the storage and disposal of the <font color="blue">materials utilized</font> in our business</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>   our <font color="blue">management</font> believes that <font color="blue">such insurance</font> has terms, including coverage     limits, which are <font color="blue">appropriate</font> for our business, <font color="blue">liabilities</font> arising from the     use, storage, handling or disposal of these <font color="blue">materials could exceed</font> our     <font color="blue">insurance coverage as well as</font> our resources</td>
    </tr>
    <tr>
      <td>We are subject to federal,     state and <font color="blue">local laws</font> and <font color="blue"><font color="blue">regulations</font> governing</font> the use, storage, handling     and disposal of these materials and <font color="blue">specified waste products</font></td>
    </tr>
    <tr>
      <td>The cost of     <font color="blue">compliance with</font> these laws and <font color="blue"><font color="blue">regulations</font> could</font> be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>To our     knowledge, we have not been, and currently are not, the subject of any     <font color="blue"><font color="blue">government</font>al investigation concerning</font> the violation of these federal, state     and <font color="blue">local laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will not     be the subject of future investigations by <font color="blue">government</font>al <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>We and our products are subject to strict <font color="blue">government</font> regulation, which may     limit the <font color="blue">development</font> of <font color="blue">products by</font> us or our <font color="blue">collaborator</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Regulation </font>by <font color="blue">government</font>al entities <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and other countries     will  be  a  <font color="blue">significant</font> factor in the production and marketing of any     <font color="blue">pharmaceutical</font> products our <font color="blue">collaborator</font>s or we may develop</td>
    </tr>
    <tr>
      <td>The nature and     the extent to which <font color="blue">government</font> regulation may apply to our <font color="blue">collaborator</font>s and     <font color="blue">us will vary depending on</font> the nature of the <font color="blue">pharmaceutical</font> products, if any</td>
    </tr>
    <tr>
      <td><font color="blue">Virtually </font>all <font color="blue">pharmaceutical</font> products require <font color="blue">regulatory</font> approval prior to     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">collaborator</font>s or <font color="blue">licensees fail</font> to obtain,     or <font color="blue">encounter delays</font> in obtaining or maintaining, <font color="blue">regulatory</font> approvals, our     financial results could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Similar <font color="blue">regulatory</font> procedures     are required in <font color="blue">countries outside</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In addition, new legislation related to <font color="blue">health care <font color="blue">could reduce</font></font> the prices     <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies can charge for drugs they sell     which,  in turn, <font color="blue">could reduce</font> the amounts that they have available for     <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font> with us</td>
    </tr>
    <tr>
      <td>If <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     <font color="blue">companies decrease</font> the resources they devote to the research and <font color="blue">development</font>     of new drugs, the number of <font color="blue">collaboration</font>s we conclude could be <font color="blue">adversely</font>     impacted  and  our  revenue  and <font color="blue">profitability</font> reduced</td>
    </tr>
    <tr>
      <td>If prices that     <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies can charge for drugs they sell     decrease, the royalties, if any, we receive from the sale of <font color="blue">products would</font>     also decrease, which would reduce our revenue and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________       <font color="blue">Failure  </font>to  attract and retain skilled personnel could <font color="blue">materially</font> and     <font color="blue">adversely</font> affect us</td>
    </tr>
    <tr>
      <td>We are a small company, and our <font color="blue">success depends</font> in part on the continued     service of <font color="blue">key scientific</font> and <font color="blue">management</font> personnel, including our president     and <font color="blue">chief executive officer</font> Leslie J Browne, Ph</td>
    </tr>
    <tr>
      <td>D, and our ability to     identify, hire and retain <font color="blue">additional</font> personnel</td>
    </tr>
    <tr>
      <td>There is intense <font color="blue">competition</font>     for <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Immigration </font><font color="blue">laws may further restrict</font> our ability     to attract or hire <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We may not be able to continue to     attract and retain the personnel <font color="blue">necessary</font> for our growth and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Failure to attract and retain key personnel could have a material adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Further, we are <font color="blue">highly dependent on</font> the <font color="blue">principal members</font> of our scientific     and <font color="blue">management</font> staff</td>
    </tr>
    <tr>
      <td>One or more of these key employees could retire or     otherwise leave our employ within the <font color="blue">foreseeable future</font>, and the loss of     any of these people could have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">development</font> and marketing <font color="blue">activities</font> are, or will be, conducted     by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">third parties</font> fail to perform their functions     <font color="blue">satisfactorily</font>,  our revenue and <font color="blue">earnings could</font> be delayed, reduced or     eliminated</td>
    </tr>
    <tr>
      <td>The  ultimate  success  of  our business plan <font color="blue">heavily depends upon</font> the     successful <font color="blue">discovery</font>, <font color="blue">development</font> and <font color="blue">commercialization</font> of <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">endeavors will</font> result in <font color="blue">commercialize</font>d <font color="blue">pharmaceutical</font>     products,  if  at all, only after <font color="blue">significant</font> preclinical and clinical     <font color="blue">development</font>, requisite <font color="blue">regulatory</font> approvals, establishment of <font color="blue">manufacturing</font>     <font color="blue">capabilities</font>  and  successful  marketing</td>
    </tr>
    <tr>
      <td>We do not currently have the     <font color="blue">technology</font>, <font color="blue">facilities</font>, personnel or experience to accomplish all of these     tasks on our own, and we <font color="blue">will likely</font> not have all the <font color="blue">necessary</font> resources in     the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Therefore, we continue to <font color="blue">depend heavily upon</font> the     expertise and <font color="blue">dedication</font> of <font color="blue">sufficient resources by partners</font> to develop and     <font color="blue">commercialize</font> products primarily <font color="blue">based on</font> lead compounds discovered by us</td>
    </tr>
    <tr>
      <td>If a partner fails to develop or <font color="blue">commercialize</font> a compound or product with     respect  to which it has rights from us, we may not receive any future     milestone payments or royalties associated with that compound or product</td>
    </tr>
    <tr>
      <td>Similarly,  while  we are unaware of a <font color="blue">specific reason</font> that any of the     following  <font color="blue">factors will</font> be experienced by our strategic <font color="blue">collaborator</font>s,     because we <font color="blue">rely heavily on them</font>, our <font color="blue">revenue could</font> be <font color="blue"><font color="blue">adversely</font> affected</font> if     our <font color="blue">collaborator</font>s:       ·  terminate their alliances or <font color="blue">arrangement</font>s with us;       ·       fail to select a target or product candidate we have identified for     subsequent <font color="blue">development</font>;       ·        fail  to  gain the requisite <font color="blue">regulatory</font> approvals for product     <font color="blue">candidates</font>;       ·       do not <font color="blue">successfully</font> <font color="blue">commercialize</font> products <font color="blue">based on</font> the compounds     that we originate;       ·       do not conduct their <font color="blue">collaborative</font> <font color="blue">activities</font> in a timely manner;       ·       do not <font color="blue">devote sufficient</font> time or resources to our <font color="blue">partnered programs</font>     or <font color="blue">potential products</font>;       ·       develop, <font color="blue">either alone</font> or with others, products that may <font color="blue">compete with</font>     our product <font color="blue">candidates</font>;       ·       dispute our <font color="blue">respective allocations</font> of rights to any products or     <font color="blue">technology</font> developed during our <font color="blue">collaboration</font>s; or       ·       <font color="blue">merge with</font> or are acquired by a <font color="blue">third party</font> that seeks to terminate     our <font color="blue">collaboration</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">risks associated with</font> the operation of an <font color="blue">international</font>     business</td>
    </tr>
    <tr>
      <td>In the year ended <font color="blue">December </font>31, 2005, <font color="blue">approximately</font> 61prca of our revenue was     derived  <font color="blue">from customers outside</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>During that period,     <font color="blue">approximately</font> 60prca of our revenue was derived from customers in Europe, and     <font color="blue">approximately</font> 1prca was derived from customers in the Asia/Pacific region</td>
    </tr>
    <tr>
      <td>We     anticipate  that  <font color="blue">international</font> revenue <font color="blue">will continue</font> to account for a     <font color="blue">significant</font> percentage of our <font color="blue">overall revenue</font></td>
    </tr>
    <tr>
      <td>While we are unaware of a     <font color="blue">specific reason</font> that any of the <font color="blue"><font color="blue">following factors</font> will</font> have a material       25     ______________________________________________________________________       <font color="blue">impact on</font> our revenue, our <font color="blue">international</font> <font color="blue">operations</font> are subject to the risk     <font color="blue">factors inherent</font> in the conduct of <font color="blue">international</font> business, including:       ·       unexpected changes in <font color="blue">regulatory</font> requirements;       ·       <font color="blue">longer payment cycles</font>;       ·       import and <font color="blue">export license requirements</font>;       ·       tariffs and other barriers;       ·       political and <font color="blue">economic instability</font>;       ·       limited <font color="blue"><font color="blue">intellectual</font> property protection</font>;       ·       <font color="blue">difficult</font>ies in <font color="blue">collecting trade receivables</font>;       ·        <font color="blue">difficult</font>ies  in  staffing and <font color="blue">managing foreign joint venture</font>     <font color="blue">operations</font>; and       ·       <font color="blue">potentially adverse tax consequences</font></td>
    </tr>
    <tr>
      <td>We may not be able to sustain or increase our <font color="blue">international</font> revenue</td>
    </tr>
    <tr>
      <td>Any of     the  foregoing  factors  may  have  a  material  adverse effect on our     <font color="blue">international</font> <font color="blue">operations</font> and, therefore, our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not realize <font color="blue">revenue from</font> our business <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font> involve lengthy negotiation cycles, often     requiring  us to expend considerable financial and <font color="blue">personnel resources</font>     without  any  assurance  that <font color="blue">revenue will</font> be recognized</td>
    </tr>
    <tr>
      <td>Factors include the strategic     nature  of  our  <font color="blue">partnerships</font>, the size of many such <font color="blue">transaction</font>s, the     <font color="blue">confidential</font> and <font color="blue">proprietary</font> nature of the <font color="blue">biological targets against which</font>     we screen our <font color="blue">chemical compound libraries</font>, and the <font color="blue">unique terms typically</font>     found in each of the <font color="blue">transaction</font>s</td>
    </tr>
    <tr>
      <td>As a result, we may expend substantial     funds and effort to negotiate <font color="blue"><font color="blue">agreement</font>s</font> for <font color="blue">collaborative</font> <font color="blue">arrangement</font>s, but     may ultimately be unable to complete the <font color="blue">transaction</font> and recognize revenue</td>
    </tr>
    <tr>
      <td>In these <font color="blue">circumstances</font>, our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font> will be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> may be <font color="blue">interrupted by</font> the occurrence of a <font color="blue">natural disaster</font> or     other <font color="blue"><font color="blue">catastrophic</font> event at</font> our <font color="blue">primary <font color="blue">facilities</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our <font color="blue">laboratories</font> and equipment for the <font color="blue">continued operation</font> of     our business</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> <font color="blue">operations</font> and <font color="blue">administrative</font>     functions are <font color="blue">primarily conducted at</font> our <font color="blue">facilities</font> in the Princeton, New     Jersey  area</td>
    </tr>
    <tr>
      <td>Although we have <font color="blue">contingency</font> plans in effect for natural     <font color="blue">disasters</font> or other <font color="blue">catastrophic</font> events, <font color="blue">catastrophic</font> events could still     disrupt our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Even though we carry business <font color="blue">interruption <font color="blue">insurance policies</font></font>, we may suffer     losses  as a result of business <font color="blue">interruptions</font> that exceed the coverage     <font color="blue">available under</font> our <font color="blue">insurance policies</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">natural disaster</font> or <font color="blue">catastrophic</font>     event in our <font color="blue">facilities</font> or the areas in which they are <font color="blue">located could</font> have a     <font color="blue">significant</font> negative <font color="blue">impact on</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we  do  not intend to <font color="blue">pay dividends</font>, you <font color="blue">will benefit from</font> an     <font color="blue">investment</font> in our <font color="blue">common stock</font> only if it appreciates in value</td>
    </tr>
    <tr>
      <td>We  have  never declared or paid any cash dividend on <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">currently intend</font> to retain our <font color="blue">future earnings</font>, if any, to finance the     expansion of our business and do not expect to pay any <font color="blue">cash dividends</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>As a result, the success of your <font color="blue">investment</font> in our     <font color="blue">common stock</font> will depend entirely upon any future <font color="blue">appreciation</font> in its value</td>
    </tr>
    <tr>
      <td>There is no guarantee that our <font color="blue">common stock</font> will appreciate in value or even     maintain its price</td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________       Anti-takeover  provisions  under  Section 203  of the <font color="blue">Delaware </font>General     Corporation Law, provisions in our amended and <font color="blue">restated certificate</font> of     <font color="blue">incorporation</font>  and  amended and <font color="blue">restated bylaws</font>, and our adoption of a     <font color="blue">stockholder rights</font> plan may render more <font color="blue">difficult</font> the <font color="blue">accomplishment</font> of     mergers or the <font color="blue">assumption</font> of <font color="blue">control by</font> a <font color="blue">principal stockholder</font>, making more     <font color="blue">difficult</font> the removal of <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Section 203 of the <font color="blue"><font color="blue">Delaware </font>General Corporation Law </font>may delay or deter     attempts  to  <font color="blue">secure control</font> of our <font color="blue">company without</font> the consent of our     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>In general, Section 203 prohibits a publicly-held <font color="blue"><font color="blue">Delaware </font>    </font><font color="blue">corporation from</font> engaging in a business <font color="blue"><font color="blue">combination</font> with</font> an interested     stockholder  for a period of <font color="blue">three years following</font> the date the person     becomes an interested stockholder, unless certain conditions are met</td>
    </tr>
    <tr>
      <td>Our  amended and <font color="blue">restated certificate</font> of <font color="blue">incorporation</font> and amended and     <font color="blue">restated bylaws</font> contain several provisions that <font color="blue">could delay</font> or make more     <font color="blue">difficult</font> the <font color="blue">acquisition</font> of our <font color="blue">company through</font> a <font color="blue">hostile tender offer</font>,     open market purchases, <font color="blue">proxy contest</font>, merger or other <font color="blue">takeover attempt</font> that     a stockholder might consider in his or her <font color="blue">best interest</font>, including those     attempts that might result in a <font color="blue">premium over</font> the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>Such provisions include the issuance of <font color="blue">preferred stock without</font>     approval of the holders of our <font color="blue">common stock</font>, the classification of our board     of <font color="blue">directors</font>, the election and removal of <font color="blue">directors</font>, restrictions on the     ability of <font color="blue">stockholders</font> to take <font color="blue">action without</font> a meeting, restrictions on     <font color="blue">stockholders</font>’  ability  to  call  a <font color="blue">special meeting</font> and advance notice     procedures regarding any proposal of stockholder business to be <font color="blue">discussed at</font>     a <font color="blue"><font color="blue">stockholders</font> meeting</font></td>
    </tr>
    <tr>
      <td>We  have  adopted  a  <font color="blue">stockholder rights</font> plan, which is <font color="blue">triggered upon</font>     <font color="blue">commencement</font> or <font color="blue">announcement</font> of a <font color="blue">hostile tender offer</font> or when any one     person or group acquires 15prca or more of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The rights plan,     once triggered, enables <font color="blue">stockholders</font> to purchase our <font color="blue">common stock</font> at reduced     prices</td>
    </tr>
    <tr>
      <td>These provisions of our governing documents, <font color="blue">stockholder rights</font> plan     and <font color="blue">Delaware </font>law could have the effect of delaying, deferring or preventing     a change of control, including <font color="blue">without limitation</font> a <font color="blue">proxy contest</font>, making     more <font color="blue">difficult</font> the <font color="blue">acquisition</font> of a substantial block of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">provisions could also limit</font> the price that investors might be willing to     pay in the future for shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Further, the existence of     these anti-takeover measures may cause potential bidders to look elsewhere,     rather than initiating <font color="blue">acquisition</font> <font color="blue">discussions</font> with us</td>
    </tr>
    <tr>
      <td>If we engage in an <font color="blue">acquisition</font> or business <font color="blue">combination</font>, we will incur a     variety of risks that could <font color="blue">adversely</font> affect our business <font color="blue">operations</font> or our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>From time to time we have considered, and we <font color="blue">will continue</font> to consider in     the future, if and when any <font color="blue">appropriate</font> opportunities become available,     strategic business <font color="blue">initiatives intended</font> to further the <font color="blue">development</font> of our     business</td>
    </tr>
    <tr>
      <td>These <font color="blue">initiatives may</font> include acquiring products, <font color="blue">businesses</font> or <font color="blue">technologies</font>     or <font color="blue">entering into</font> a business <font color="blue"><font color="blue">combination</font> with</font> another company</td>
    </tr>
    <tr>
      <td>If we do     <font color="blue">pursue such</font> a strategy, we could, among other things:       ·         issue  equity  securities  that  would  dilute  our  current     <font color="blue">stockholders</font>’ percentage ownership;       ·       incur substantial debt that may place <font color="blue">strains on</font> our <font color="blue">operations</font>;       ·       spend substantial operational, financial and <font color="blue">management</font> resources in     integrating new <font color="blue">businesses</font>, <font color="blue">technologies</font> and products;       ·       assume substantial actual or contingent <font color="blue">liabilities</font>; or       ·       <font color="blue">merge with</font>, or <font color="blue">otherwise <font color="blue">enter into</font></font> a business <font color="blue"><font color="blue">combination</font> with</font>,     another company in which our <font color="blue">stockholders</font> would receive cash or shares of     the other company or a <font color="blue">combination</font> of <font color="blue">both on terms</font> that our <font color="blue">stockholders</font>     may not deem desirable</td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________       We are not in a position to predict what, if any, <font color="blue">collaboration</font>s, alliances     or other <font color="blue">transaction</font>s may result or how, when or if these <font color="blue">activities</font> would     have a material effect on us or the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO ESTABLISHING OUR COMPANY AS INDEPENDENT FROM ACCELRYS       We have agreed to <font color="blue">certain restrictions</font> to preserve the <font color="blue">tax treatment</font> of the     <font color="blue">distribution</font>, which will reduce our strategic and operating <font color="blue">flexibility</font></td>
    </tr>
    <tr>
      <td><font color="blue">Accelrys </font>obtained an <font color="blue">opinion from</font> Dechert LLP, its counsel, to the effect     that the April 30, 2004 dividend <font color="blue">distribution</font> of shares of our <font color="blue">common stock</font>     <font color="blue">qualifies as</font> a <font color="blue">transaction</font> that is <font color="blue">generally</font> tax-free under Sections 355     and/or 368(a)(1)(D) of the <font color="blue">Internal Revenue Code </font>of 1986, as amended (the     “Code”)</td>
    </tr>
    <tr>
      <td><font color="blue">Current  </font>tax  law  <font color="blue">generally</font>  creates a <font color="blue">presumption</font> that the     <font color="blue">distribution</font> would be taxable to <font color="blue">Accelrys </font>but not to its <font color="blue">stockholders</font> if we     engage in, or <font color="blue">enter into</font> an <font color="blue">agreement</font> to engage in, a <font color="blue">transaction</font> that would     result in a 50 percent or greater change by vote or by value in our stock     <font color="blue">ownership during</font> the four-year period beginning on the date that <font color="blue">begins two</font>     years  before the <font color="blue">distribution</font> date, unless it is established that the     <font color="blue">transaction</font> is not pursuant to a plan or series of <font color="blue">transaction</font>s related to     the <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td><font color="blue">Temporary US Treasury </font><font color="blue">regulations</font> currently in effect <font color="blue">generally</font> provide     that whether an <font color="blue">acquisition</font> <font color="blue">transaction</font> and a <font color="blue">distribution</font> are part of a     plan is determined <font color="blue">based on</font> all of the facts and <font color="blue">circumstances</font>, including     but not limited to those <font color="blue">specific factors listed</font> in the <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In     addition, the <font color="blue">regulations</font> provide several “safe harbors” for <font color="blue">acquisition</font>     <font color="blue">transaction</font>s that are not considered to be part of a plan</td>
    </tr>
    <tr>
      <td>We and <font color="blue">Accelrys </font>have <font color="blue">entered into</font> a tax sharing <font color="blue">agreement</font> under which we     have  made  certain  covenants  to  each  other in <font color="blue"><font color="blue">connection</font> with</font> the     <font color="blue">distribution</font> that we may not take <font color="blue">certain actions without first</font> obtaining an     <font color="blue">unqualified opinion</font> of counsel or an <font color="blue">Internal Revenue Service </font>ruling that     <font color="blue">such actions will</font> not cause the <font color="blue">distribution</font> to <font color="blue">become taxable</font></td>
    </tr>
    <tr>
      <td>Pursuant to     these covenants, <font color="blue">generally</font> (1) we will, for two years after the <font color="blue">distribution</font>     date, continue the active conduct of the <font color="blue">drug <font color="blue">discovery</font></font> business; (2) we     will not repurchase our <font color="blue">stock except</font> in certain <font color="blue">circumstances</font> permitted by     the Internal Revenue Service; (3) we will not take any actions in<font color="blue">consistent</font>     with the <font color="blue">representations</font> made in <font color="blue"><font color="blue">connection</font> with</font> the <font color="blue">issuance by</font> <font color="blue">Dechert LLP </font>    of its opinion with respect to the <font color="blue">distribution</font>; and (4) we will not take or     fail to take any other action that would result in any tax being <font color="blue">imposed on</font>     the  <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td><font color="blue">Accelrys </font> may  seek an injunction to enforce these     covenants</td>
    </tr>
    <tr>
      <td>These restrictions could <font color="blue">substantially</font> limit our strategic and operational     <font color="blue">flexibility</font>, including our ability to finance our <font color="blue">operations</font> by issuing     equity  securities,  to  make <font color="blue"><font color="blue">acquisition</font>s</font> using <font color="blue">equity securities</font>, to     repurchase our <font color="blue">equity securities</font>, to <font color="blue">raise money by selling assets</font>, or to     <font color="blue">enter into</font> business <font color="blue">combination</font> <font color="blue">transaction</font>s</td>
    </tr>
    <tr>
      <td>We have agreed to indemnify <font color="blue">Accelrys </font>for taxes and related losses resulting     from any actions we take that cause the <font color="blue">distribution</font> to fail to qualify as a     tax-free <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>We  have agreed to indemnify <font color="blue">Accelrys </font>for any taxes and related losses     (including any <font color="blue">applicable interest</font> and penalties, all related <font color="blue">accounting</font>,     legal and other <font color="blue">professional fees</font>, all related <font color="blue">court costs</font> and all costs,     expenses and <font color="blue">damages associated with</font> related stockholder <font color="blue">litigation</font> or     <font color="blue">controversies</font>  and  any  amount  paid  in  respect of the <font color="blue">liability</font> of     <font color="blue">stockholders</font>) resulting from a breach of any of the <font color="blue">covenants described</font>     above</td>
    </tr>
    <tr>
      <td>Furthermore, we will be responsible for taxes that may be imposed     upon <font color="blue">Accelrys </font>pursuant to section 355(e) of the Code in <font color="blue"><font color="blue">connection</font> with</font> a     <font color="blue">transaction</font> that results in a change in control of us, even though we will     have obtained an <font color="blue">Internal Revenue Service </font>ruling or an <font color="blue">unqualified opinion</font>     of <font color="blue">counsel prior</font> to the <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>The amount of any <font color="blue">indemnification</font>     <font color="blue">payments could</font> be substantial</td>
    </tr>
    <tr>
      <td>The amount of <font color="blue">Accelrys </font>taxes for which we are     agreeing to indemnify <font color="blue">Accelrys </font>will be <font color="blue">based on</font> the excess of the aggregate     <font color="blue">fair market value</font> of our stock as of the April 30, 2004 <font color="blue">distribution</font> date     over the <font color="blue">Accelrys </font>tax basis in our stock</td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________       We may be required to indemnify Accelrys, or may not be able to collect on     <font color="blue">indemnification</font> rights from Accelrys</td>
    </tr>
    <tr>
      <td>Under the terms of the <font color="blue">master separation</font> and <font color="blue">distribution</font> <font color="blue">agreement</font> and the     tax  sharing  and  <font color="blue">indemnification</font> <font color="blue">agreement</font> that we <font color="blue">entered into</font> with     Accelrys, we and <font color="blue">Accelrys </font>agreed to <font color="blue">indemnify one</font> another from and after the     <font color="blue">distribution</font> with respect to the indebtedness, <font color="blue">liabilities</font> and <font color="blue">obligations</font>     retained by our <font color="blue">respective companies</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">indemnification</font> <font color="blue">obligations</font>     could  be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>Our ability to satisfy any such <font color="blue">indemnification</font>     <font color="blue">obligations</font> will depend upon the <font color="blue">future financial strength</font> of our company</td>
    </tr>
    <tr>
      <td>We cannot determine whether we will have to indemnify <font color="blue">Accelrys </font>for any     substantial <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot assure</font> you that, if <font color="blue">Accelrys </font><font color="blue">becomes obligated</font> to indemnify     us  for any substantial <font color="blue">obligations</font>, <font color="blue">Accelrys </font>will have the ability to     satisfy those <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">payment by</font> <font color="blue">Accelrys </font>or us pursuant to these     <font color="blue">indemnification</font> provisions could have a material adverse effect on the     payor’s  business</td>
    </tr>
    <tr>
      <td>Any  failure  by  <font color="blue">Accelrys </font> or  us  to satisfy its     <font color="blue">indemnification</font> <font color="blue">obligations</font> could have a material adverse effect on the     other company’s business</td>
    </tr>
    <tr>
      <td>CERTAIN RISKS RELATED TO INTELLECTUAL PROPERTY       Positions taken by the <font color="blue">US Patent and Trademark Office </font>or non-US patent     and trademark officials may preclude us from obtaining sufficient or timely     protection for our <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies are     uncertain and <font color="blue">involve complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>The coverage     claimed in a patent <font color="blue">application</font> can be <font color="blue"><font color="blue">significant</font>ly</font> reduced before the     patent is issued</td>
    </tr>
    <tr>
      <td>There is a <font color="blue">significant</font> risk that the scope of a <font color="blue">patent may</font>     not be sufficient to prevent <font color="blue">third parties</font> from marketing other products or     <font color="blue">technologies</font> with the <font color="blue">same functionality</font> of our products and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Consequently, some or all of our patent <font color="blue">application</font>s may not <font color="blue">issue into</font>     patents, and any issued <font color="blue">patents may</font> provide in<font color="blue">effective</font> remedies or be     challenged or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> have filed patent <font color="blue">application</font>s of which we may or may not     have knowledge, and which may <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">application</font>s <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>are maintained in secrecy for 18     <font color="blue">months from filing</font> or until a <font color="blue">patent issues</font></td>
    </tr>
    <tr>
      <td>Under certain <font color="blue">circumstances</font>,     patent  <font color="blue">application</font>s  are  <font color="blue">never published but remain</font> in <font color="blue">secrecy until</font>     issuance</td>
    </tr>
    <tr>
      <td>As  a result, others may have filed patent <font color="blue">application</font>s for     products or <font color="blue">technology</font> covered by one or more pending patent <font color="blue">application</font>s     upon which we are relying</td>
    </tr>
    <tr>
      <td>If <font color="blue">application</font>s covering similar <font color="blue">technologies</font>     were to be filed before our <font color="blue">application</font>s, our patent <font color="blue">application</font>s may not be     granted</td>
    </tr>
    <tr>
      <td>There may be third-party patents, patent <font color="blue">application</font>s and other     <font color="blue">intellectual</font> property or information relevant to our <font color="blue">chemical compositions</font>     and other <font color="blue">technologies</font> that are not known to us, that block us or compete     with our <font color="blue">chemical compositions</font> or other <font color="blue">technologies</font>, or limit the scope of     <font color="blue">patent protection available</font> to us</td>
    </tr>
    <tr>
      <td>Moreover, from time to time, <font color="blue">patents may</font>     issue  which  block or <font color="blue">compete with</font> our <font color="blue">chemical compositions</font> or other     <font color="blue">technologies</font>, or limit the scope of <font color="blue">patent protection available</font> to us</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be <font color="blue">necessary</font> to <font color="blue">enforce <font color="blue">patents issued</font></font> to us or to determine     the scope and validity of the <font color="blue"><font color="blue">intellectual</font> property rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">protect adequately</font> the <font color="blue">trade secrets</font> and <font color="blue">confidential</font>     information that we disclose to our employees</td>
    </tr>
    <tr>
      <td>We rely upon <font color="blue">trade secrets</font>, technical know-how and continuing <font color="blue">technological</font>     innovation to develop and maintain our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors     </font>through their independent <font color="blue">discovery</font> (or improper means, <font color="blue">such as unauthorized</font>     <font color="blue">disclosure</font>  or  industrial espionage) may come to know our <font color="blue">proprietary</font>     information</td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> require employees and <font color="blue">consultants</font> to execute     <font color="blue"><font color="blue">confidential</font>ity</font> and assignment-of-<font color="blue">inventions</font> <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreement</font>s</font>     <font color="blue">typically provide</font> that all materials and <font color="blue">confidential</font> information       29     ______________________________________________________________________       developed by or made known to the employee or <font color="blue">consultant during</font> his, her or     its  <font color="blue">relationship</font>  with  us  are to be kept <font color="blue">confidential</font>, and that all     <font color="blue">inventions</font>  arising out of the employee’s <font color="blue">relationship</font> with us are our     exclusive  property</td>
    </tr>
    <tr>
      <td>Our  employees  and <font color="blue">consultants</font> may breach these     <font color="blue"><font color="blue">agreement</font>s</font>,  and in some instances we may not have an <font color="blue">adequate remedy</font></td>
    </tr>
    <tr>
      <td>Additionally,  in  some  instances, we may have failed to require that     employees     and     <font color="blue">consultants</font>    execute    <font color="blue"><font color="blue">confidential</font>ity</font>    and     assignment-of-<font color="blue">inventions</font> <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Foreign laws may not <font color="blue">afford us sufficient protections</font> for our <font color="blue">intellectual</font>     property, and we may not <font color="blue">seek patent protection outside</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue">success depends</font>, in part, upon our ability to obtain     <font color="blue">international</font> protection for our <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>However, the laws of     some foreign countries may not be as <font color="blue">comprehensive</font> as those of the United     States and may not be sufficient to protect our <font color="blue">proprietary</font> rights abroad</td>
    </tr>
    <tr>
      <td>In addition, we may decide not to <font color="blue">pursue patent protection outside</font> the     <font color="blue"><font color="blue">United States</font> </font>because of cost and <font color="blue"><font color="blue">confidential</font>ity</font> concerns</td>
    </tr>
    <tr>
      <td>Accordingly, our     <font color="blue">international</font> <font color="blue">competitors</font> could obtain foreign patent protection for, and     market overseas, products and <font color="blue">technologies</font> for which we are seeking US     patent  protection  and  they  may  be  able to use these products and     <font color="blue">technologies</font> to <font color="blue">compete against us</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">adequately defend</font> our <font color="blue">intellectual</font> property from third     <font color="blue">party <font color="blue">infringement</font></font>, and <font color="blue">third party</font> challenges to our <font color="blue">intellectual</font> property     may <font color="blue">adversely</font> affect our rights and be costly and time consuming</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> have, or are <font color="blue">affiliated</font> with companies having,     <font color="blue">substantially</font> greater <font color="blue">resources than</font> we have, and those <font color="blue">competitors</font> may be     able to sustain the costs of complex patent <font color="blue">litigation</font> to a <font color="blue">greater degree</font>     and for <font color="blue">longer periods</font> of time than us</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>resulting from the     <font color="blue">initiation</font> and <font color="blue">continuation</font> of any patent or related <font color="blue">litigation</font> could have a     material adverse effect on our ability to compete in the <font color="blue">marketplace pending</font>     resolution of the <font color="blue">disputed matters</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> prepare and file     patent <font color="blue">application</font>s <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>that claim <font color="blue">technology</font> also claimed     by us, we may have to <font color="blue">participate</font> in <font color="blue">interference <font color="blue">proceedings</font></font> declared by     the <font color="blue">US Patent and Trademark Office </font>to determine the priority of invention,     which  could result in substantial costs to us, even if the outcome is     favorable to us</td>
    </tr>
    <tr>
      <td>Similarly, <font color="blue">opposition <font color="blue">proceedings</font> may</font> occur overseas, which     may result in the loss or narrowing of the scope of claims or <font color="blue">legal rights</font></td>
    </tr>
    <tr>
      <td>Such  <font color="blue">proceedings</font>  will  at  least  result in delay in the issuance of     enforceable claims</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse outcome could</font> subject us to <font color="blue">significant</font>     <font color="blue">liabilities</font> to <font color="blue">third parties</font> and require us to <font color="blue">license disputed rights from</font>     <font color="blue">third parties</font> or <font color="blue">cease using</font> the <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>A patent issued to us may not be <font color="blue">sufficiently broad</font> to <font color="blue">protect adequately</font>     our rights in <font color="blue">intellectual</font> property to which the patent relates</td>
    </tr>
    <tr>
      <td>Even if patents are issued to us, these <font color="blue">patents may</font> not <font color="blue">sufficiently protect</font>     our interest in our <font color="blue">chemical compositions</font> or other <font color="blue">technologies</font> because the     scope of <font color="blue">protection provided by</font> any <font color="blue">patents issued</font> to or <font color="blue">licensed by us</font> are     subject to the <font color="blue">uncertainties</font> inherent in <font color="blue">patent law</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> be     able to <font color="blue">design around</font> these patents or develop <font color="blue">unique products providing</font>     effects similar to our products</td>
    </tr>
    <tr>
      <td>In addition, others may discover uses for     our <font color="blue">chemical compositions</font> or <font color="blue">technologies</font> other than those uses covered in     our patents, and these other uses may be <font color="blue">separately patentable</font></td>
    </tr>
    <tr>
      <td>A number of     <font color="blue">pharmaceutical</font>  and bio<font color="blue">technology</font> companies, and research and academic     <font color="blue">institutions</font>, have developed <font color="blue">technologies</font>, filed patent <font color="blue">application</font>s or     received  patents  on  various <font color="blue">technologies</font> that may be related to our     business</td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">technologies</font>, patent <font color="blue">application</font>s or <font color="blue">patents may</font>     conflict  with our <font color="blue">technologies</font>, patent <font color="blue">application</font>s or patents</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">conflicts could also limit</font> the scope of patents, if any, that we may be able     to obtain, or result in the denial of our patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>We are not     <font color="blue">currently aware</font> of any such patent <font color="blue">application</font>s or patents that could have a     material adverse effect on our business</td>
    </tr>
    <tr>
      <td>30     ______________________________________________________________________       We may be subject to claims of <font color="blue">infringement</font> by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> claim <font color="blue"><font color="blue">infringement</font> by us</font> of their <font color="blue">intellectual</font> property     rights</td>
    </tr>
    <tr>
      <td>In addition, to the extent our employees are involved in research     areas similar to those areas in which they were <font color="blue">involved at</font> their former     employers, we may be subject to claims that one of our employees, or we,     have <font color="blue">inadvertently</font> or otherwise used or disclosed the alleged <font color="blue">trade secrets</font>     or other <font color="blue">proprietary</font> information of a <font color="blue">former employer</font></td>
    </tr>
    <tr>
      <td>From time to time, we     have received letters claiming or suggesting that our products or <font color="blue">activities</font>     may infringe <font color="blue">third party</font> patents or other <font color="blue"><font color="blue">intellectual</font> property rights</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">products may infringe patent</font> or other <font color="blue"><font color="blue">intellectual</font> property rights</font> of third     parties</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">patents may</font> have <font color="blue">been issued</font> or may be issued in the     future that could cover certain aspects of our <font color="blue">technology</font> and that could     prevent us from using <font color="blue">technology</font> that we use or expect to use</td>
    </tr>
    <tr>
      <td>We may be     required to <font color="blue">seek licenses</font> for, or otherwise acquire rights to, <font color="blue">technology</font> as     a result of claims of <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>We may not possess proper ownership or     <font color="blue">access rights</font> to the <font color="blue">intellectual</font> property we use</td>
    </tr>
    <tr>
      <td>Third parties or other     companies may bring <font color="blue">infringement</font> suits against us</td>
    </tr>
    <tr>
      <td>Any claims, with or     without  merit,  could  be  time consuming to defend, result in costly     <font color="blue">litigation</font>, divert <font color="blue">management</font>’s attention and resources or require us to     <font color="blue">enter into</font> royalty or licensing <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Royalty or licensing <font color="blue"><font color="blue">agreement</font>s</font>,     if required, may not be <font color="blue">available on</font> terms acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>In     the event of a successful claim of product <font color="blue">infringement</font> against us, our     failure or <font color="blue">inability</font> to license or <font color="blue">design around</font> the infringed <font color="blue">technology</font>     could have a material adverse effect on our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are not <font color="blue">currently involved</font> in actions of this     type that are material to our business</td>
    </tr>
  </tbody>
</table>